Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study

NCT00640562 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00640562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00640562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
February 28, 2010
Enrollment
216 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

depression, schizophrenia